James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes - a podcast by PVI, PeerView Institute for Medical Education
from 2023-03-28T18:00
Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education